Safety and exploratory efficacy of bosutinib in amyotrophic lateral sclerosis: a phase 2 trial using external controls

Abstract Background Bosutinib, a selective Src/c-Abl inhibitor approved for the treatment of chronic myelogenous leukemia (CML), was identified as a molecularly targeted therapeutic candidate for amyotrophic lateral sclerosis (ALS) through induced pluripotent stem cell-based drug repurposing. To evaluate its safety and tolerability and explore its efficacy in ALS, an exploratory, multicenter, open-label phase 2 clinical trial was conducted. Methods This study included a 12-week observation period and a 24-week treatment period enrolling patients diagnosed with ALS within 2 years of symptom onset. Eligible patients were centrally allocated (1:1) to receive oral bosutinib at either 200 mg/day or 300 mg/day for 24 weeks. In lieu of a placebo control arm, efficacy was assessed using two external control datasets: placebo data of the edaravone Study MCI186-19 and registry data from the multicenter ALS cohort study, JaCALS, with outcomes evaluated by the total ALS Functional Rating Scale-Revised (ALSFRS-R). Results Between April 2022 and January 2024, 33 participants were screened, and 26 received bosutinib. Of these, 22 completed the 24-week treatment period and 4 discontinued treatment, primarily because of adverse events, with hepatic toxicity being the most common reason for discontinuation. No new safety signals specific to patients with ALS were identified. As a primary endpoint, the mean change from baseline in ALSFRS-R score at week 24 showed a smaller reduction in both dose groups compared with the placebo group in MCI186-19. The exploratory JaCALS comparison suggested a potential clinical signal of bosutinib. Exploratory biomarker analyses showed a decrease in plasma neurofilament light chain levels after treatment. Conclusions This early-phase study provides safety and tolerability data and exploratory efficacy findings for bosutinib in ALS. It also illustrates both the potential utility and limitations of external controls in a rare, rapidly progressive disease. Trial registration This trial was registered with ClinicalTrials.gov (NCT04744532) on February 9, 2021.

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2026-11-14
DOI
https://doi.org/10.1186/s12916-026-05410-w
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety and exploratory efficacy of bosutinib in amyotrophic lateral sclerosis: a phase 2 trial using external controls

Akiko Morinaga, Takehisa Hirayama, Motoki Oe, Makiko Nagai et al.
BMC Medicine
Amyotrophic Lateral Sclerosis Research
article

Safety and exploratory efficacy of bosutinib in amyotrophic lateral sclerosis: a phase 2 trial using external controls

Akiko Morinaga, Takehisa Hirayama, Motoki Oe, Makiko Nagai, Takao Kiriyama, Takashi Ayaki, Riko Tabuchi, Ritsuko Hanajima, Gen Sobue, Takashi Nagasawa, Yusuke Furukawa, Kazuma Sugie, Shotaro Haji, Hitoki Nanaura, Masahiro Nakamori, Takenobu Murakami, Naohiro Egawa, Satoshi Morita, Haruhisa Inoue, Mihoko Kobayashi, Codrin Lungu, Kazutoshi Nishiyama, Hiroshi Kataoka, Koji Fujita, Osamu Kano, Hirofumi Maruyama, Keiko Imamura, Ryosuke Takahashi, Naoki Atsuta, Yuishin Izumi, Kasia Lobello, Yasuhiro Watanabe
article en

Abstract

Abstract Background Bosutinib, a selective Src/c-Abl inhibitor approved for the treatment of chronic myelogenous leukemia (CML), was identified as a molecularly targeted therapeutic candidate for amyotrophic lateral sclerosis (ALS) through induced pluripotent stem cell-based drug repurposing. To evaluate its safety and tolerability and explore its efficacy in ALS, an exploratory, multicenter, open-label phase 2 clinical trial was conducted. Methods This study included a 12-week observation period and a 24-week treatment period enrolling patients diagnosed with ALS within 2 years of symptom onset. Eligible patients were centrally allocated (1:1) to receive oral bosutinib at either 200 mg/day or 300 mg/day for 24 weeks. In lieu of a placebo control arm, efficacy was assessed using two external control datasets: placebo data of the edaravone Study MCI186-19 and registry data from the multicenter ALS cohort study, JaCALS, with outcomes evaluated by the total ALS Functional Rating Scale-Revised (ALSFRS-R). Results Between April 2022 and January 2024, 33 participants were screened, and 26 received bosutinib. Of these, 22 completed the 24-week treatment period and 4 discontinued treatment, primarily because of adverse events, with hepatic toxicity being the most common reason for discontinuation. No new safety signals specific to patients with ALS were identified. As a primary endpoint, the mean change from baseline in ALSFRS-R score at week 24 showed a smaller reduction in both dose groups compared with the placebo group in MCI186-19. The exploratory JaCALS comparison suggested a potential clinical signal of bosutinib. Exploratory biomarker analyses showed a decrease in plasma neurofilament light chain levels after treatment. Conclusions This early-phase study provides safety and tolerability data and exploratory efficacy findings for bosutinib in ALS. It also illustrates both the potential utility and limitations of external controls in a rare, rapidly progressive disease. Trial registration This trial was registered with ClinicalTrials.gov (NCT04744532) on February 9, 2021.

BMC Medicine
Hiroshima University (JP), Toho University (JP), Aichi Medical University (JP), Pfizer (United States) (US), Akita University (JP), Kyoto University (JP), Kitasato University Hospital (JP), Pfizer (Japan) (JP), Center for iPS Cell Research and Application, Kyoto University (JP), Pfizer R&D Japan G.K. (Japan) (JP), Tottori University (JP), Kitasato University (JP), Nara Medical University (JP), Tokushima University (JP)
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon